Incorporation and Release of Chemically Intact Mitomycin C from Albumin Microspheres: a High Performance Liquid Chromatography Evaluation

被引:7
作者
Allan, Lucy [1 ,2 ]
Cummings, Jeffrey [1 ]
Willmott, Neville [2 ,3 ]
Whateley, Tony L. [2 ]
Smyth, John F. [1 ]
机构
[1] Western Gen Hosp, Med Oncol Unit, Imperial Canc Res Fund, Edinburgh EH4 2XU, Midlothian, Scotland
[2] Univ Strathclyde, Dept Pharmaceut Sci, Glasgow G1 1XW, Lanark, Scotland
[3] Celltech UK, Oncol Res, Slough, Berks, England
关键词
HPLC; mitomycin C; protein microspheres; stability;
D O I
10.3109/10611869308996090
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Preparation of mitomycin C-loaded human serum albumin (HSA) microspheres using a new technique that avoids the use of heat denaturation, which is known chemically to degrade incorporated drug, is described. This method is based on cross-linking of protein by glutaraldehye (2.2%) during emulsification (W/O) at room temperature. The resultant particles have a mean (s.d.) diameter of 16.9 (0.34) mu m (50% weight average), contain mean (s.d.) 1.15 (0.05) % mitomycin C (MMC) (w/w. n = 17) and maintain sustained release of drug over 20 h. High performance liquid chromatography (HPLC) with diode array detection was used to study the chemical integrity of the drug. Two classes of decomposition products were evaluated: chemical degradation products and drug/nucleophile covalent adducts. The HPLC separation was validated by a number of standards of proposed degradation products. To examine incorporated drug, a complete microsphere system was solubilized with 0.4% trypsin for 24 h, while to examine released drug, microspheres were immobilized on a flow-through glass wool column and fractions were collected. No evidence of significant chemical degradation or covalent coupling to protein was detected in microsphere digests. Two candidate decomposition products, representing approximately 10% of drug released from microspheres (assuming similar molar extinction coefficients to MMC), were identified in column fractions. One of these products appeared to be a covalent adduct, the other possibly an isomeric form of intact MMC. Thus, MMC is predominantly incorporated into and released (90/%) chemically intact from HSA microspheres prepared by the technique described.
引用
收藏
页码:317 / 324
页数:8
相关论文
共 41 条
[1]   A PHASE-I STUDY OF REGIONALLY ADMINISTERED MITOMYCIN MICROCAPSULES FOR PATIENTS WITH COLORECTAL LIVER METASTASES [J].
ANDERSON, JH ;
GOLDBERG, JA ;
ELEY, JG ;
WHATELEY, TL ;
KERR, DJ ;
COOKE, TG ;
MCARDLE, CS .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (09) :1189-1190
[2]   LIQUID-CHROMATOGRAPHIC AND MASS-SPECTRAL ANALYSIS OF MITOSANE AND MITOSENE DERIVATIVES OF MITOMYCIN-C [J].
ANDREWS, PA ;
PAN, SS ;
BACHUR, NR .
JOURNAL OF CHROMATOGRAPHY, 1983, 262 (JUN) :231-247
[3]   DEGRADATION OF MITOMYCIN-C IN ACID PHOSPHATE AND ACETATE BUFFER SOLUTIONS [J].
BEIJNEN, JH ;
FOKKENS, RH ;
ROSING, H ;
UNDERBERG, WJM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1986, 32 (2-3) :111-121
[4]   MITOMYCIN ANTITUMOR AGENTS - A REVIEW OF THEIR PHYSICOCHEMICAL AND ANALYTICAL PROPERTIES AND STABILITY [J].
BEIJNEN, JH ;
LINGEMAN, H ;
VANMUNSTER, HA ;
UNDERBERG, WJM .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1986, 4 (03) :275-295
[5]   ISOLATION AND STRUCTURE OF AN INTRASTRAND CROSS-LINK ADDUCT OF MITOMYCIN-C AND DNA [J].
BIZANEK, R ;
MCGUINNESS, BF ;
NAKANISHI, K ;
TOMASZ, M .
BIOCHEMISTRY, 1992, 31 (12) :3084-3091
[6]  
CARTER SK, 1979, MITOMYCIN C CURRENT
[7]  
CHEN Y, 1988, J CONTROL RELEASE, V8, P93
[8]   THE ENZYMOLOGY OF DOXORUBICIN QUINONE REDUCTION IN TUMOR-TISSUE [J].
CUMMINGS, J ;
ALLAN, L ;
WILLMOTT, N ;
RILEY, R ;
WORKMAN, P ;
SMYTH, JF .
BIOCHEMICAL PHARMACOLOGY, 1992, 44 (11) :2175-2183
[9]   ADRIAMYCIN-LOADED ALBUMIN MICROSPHERES - QUALITATIVE ASSESSMENT OF DRUG INCORPORATION AND INVITRO RELEASE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY AND HIGH-SPEED MULTI-DIODE ARRAY SPECTROPHOTOMETRIC DETECTION [J].
CUMMINGS, J ;
WILLMOTT, N .
JOURNAL OF CHROMATOGRAPHY, 1985, 343 (01) :208-212
[10]   COVALENT COUPLING OF DOXORUBICIN IN PROTEIN MICROSPHERES IS A MAJOR DETERMINANT OF TUMOR DRUG DISPOSITION [J].
CUMMINGS, J ;
WILLMOTT, N ;
MARLEY, E ;
SMYTH, J .
BIOCHEMICAL PHARMACOLOGY, 1991, 41 (12) :1849-1854